The aims of the present study are to ascertain if CD8+ T cells specific for AEs are prominent in RA patients, to distinguish which of them is associated with disease severity, and to determine if they have the potentiality to predict which patients might (or might not) benefit from therapy with TNF-α inhibitors. Here, CD8A is linked to rheumatoid arthritis.